Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
26.30
+1.55 (6.26%)
May 14, 2026, 1:17 PM EDT - Market open
Septerna Revenue
Septerna had revenue of $26.52M in the quarter ending March 31, 2026, with 12,010.96% growth. This brings the company's revenue in the last twelve months to $72.26M, up 7,295.60% year-over-year. In the year 2025, Septerna had annual revenue of $45.95M with 4,174.51% growth.
Revenue (ttm)
$72.26M
Revenue Growth
+7,295.60%
P/S Ratio
15.44
Revenue / Employee
$555,808
Employees
130
Market Cap
1.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 45.95M | 44.88M | 4,174.51% |
| Dec 31, 2024 | 1.08M | 924.00K | 611.92% |
| Dec 31, 2023 | 151.00K | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSEPN News
- 1 day ago - Septerna Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 2 days ago - Septerna reports Q1 EPS (19c), consensus (27c) - TheFly
- 2 days ago - Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 9 days ago - Septerna to Present at Bank of America Securities Health Care Conference - GlobeNewsWire
- 13 days ago - Septerna initiated with a Buy at Stifel - TheFly
- 4 weeks ago - Septerna doses first patients in SEP-479 trial - TheFly
- 4 weeks ago - Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - GlobeNewsWire
- 7 weeks ago - Septerna price target raised to $38 from $34 at JPMorgan - TheFly